10 Articles in November 2026
This Week at FDA: Peptide dispute, clinical trial legislation, and more
This Week at FDA: Peptide Dispute, Clinical Trial Legislation, and More The Regulatory Affairs Professionals Society (RAPS) published its latest weekly roundup of developments at the U.S.
November 2, 2026: HHS tells compounders it will not enforce peptide regulations
Overview of the Regulatory Action According to a report dated November 2, 2026, and flagged by the industry watchdog group Partnership for Safe Medicines, the U.S.
US Health Secretary Kennedy opens access to some unapproved peptides
HHS Secretary Robert F. Kennedy Jr. Moves to Expand Access to Unapproved Peptides Health and Human Services Secretary Robert F. Kennedy Jr. has taken action to open access to certain unapproved peptide compounds, according to a report from Reuters.
Peptide FDA Updates: Latest News on Compounding and More
FDA Intensifies Scrutiny of Compounded Peptides Amid Growing Industry Demand The U.S. Food and Drug Administration continues to sharpen its regulatory focus on compounded peptide products, according to a recent report from GoodRx examining the evolving legal landscape for popular peptide therapies.
Trump administration will allow pharmacies to make popular peptides
Trump Administration Reportedly Set to Allow Compounding Pharmacies to Make Popular Peptides The Trump administration will permit pharmacies to compound certain popular peptide medications, according to a report from NPR.
HHS moves to allow compounding of some unapproved peptides
HHS Moves to Allow Compounding of Some Unapproved Peptides The U.S. Department of Health and Human Services is taking steps that would permit pharmacies to compound certain peptide drugs that currently lack FDA approval, according to a report from STAT News.
FDA scientists opposed Trump administration’s move to ease peptide access
FDA Scientists Reportedly Pushed Back Against Trump Administration Effort to Loosen Peptide Regulations Scientists within the Food and Drug Administration reportedly raised internal objections to a Trump administration push to ease regulatory restrictions on peptide-based compounds, according to a ...
October 26, 2026: PSM files citizen petition asking FDA not to allow compounding of peptides
Patient Safety Group Petitions FDA to Bar Compounding of Peptide Drugs The Partnership for Safe Medicines (PSM), a nonprofit advocacy coalition focused on drug safety and counterfeit medication risks, filed a citizen petition with the U.S.
Here's How The FDA's Temporary Peptide Compounding Policy Impacts Access, Costs And Safety
Overview of the Regulatory Action The U.S. Food and Drug Administration's evolving approach to peptide compounding has become one of the most closely watched regulatory stories in pharmaceutical law over the past two years.
GLP-1 Compounding After Drug Shortages
FDA Shortage Resolution Triggers Legal Reckoning for Compounded GLP-1 Drugs The regulatory status of compounded versions of popular GLP-1 receptor agonists like semaglutide and tirzepatide remains a contentious legal issue following the Food and Drug Administration's determination that shortages of...